|
The goal of our platforms is to increase the level of phenotyping in our cohorts by studying invasive (biopsy) and non-invasive biomarkers to better characterize rejection activity, stage and response to therapy.
|
HLA platformThis platform focuses on the study of anti-HLA and non anti-HLA DSA characteristics that have been proven to be associated with allograft survival, such as:
- antibody level and strength by Luminex® Single Antigen - antibody complement-binding capacity (C1qScreen™ by Luminex® xMAP® technology) - antibody subclass composition (IgG1, 2, 3, 4) and affinities - non anti-HLA DSAs Contact: Pr. Jean-Luc Taupin |
BioinformaticsThis platform performs large-scale data analysis to make sense out of the biological data generated by the other platforms using a high performance computing server: Intel dual Xeon Platinium 8276 for a total of 112 nodes, 16 SSD in RAID6 for more than 40To of data and more than 50 Go of DDR4 RAM. Mindful of the importance of data protection, we use an internal isolated server for analysis only and an outsourced server dedicated to file transfer using disk encryption and secure channels for transmission of data.
This platform benefits from the expertise of bioinformaticians, biological scientists, biostatisticians and machine-learning engineers offering a multidisciplinary expertise to support other teams in the analysis of RNA sequencing, Nanostring data and microarray as well as more complex downstream analysis. Based on the molecular profile of rejection on kidney transplant, we are currently developing tools to establish the diagnosis of biopsies using solely molecular data. Contacts: Clément Coudereau |
Pathology platformThis platform is dedicated to multi-organ routine techniques for high quality deep phenotyping of biopsies by routine immunostaining (immunohistochemistry and immunofluorescence: masson's trichrome, hematoxilin/eosin, complement and macrophage staining) following the current worldwide diagnosis nomenclature systems.
The platform also works on developing multiplex immunofluorescence staining as a way to improve understanding of localization and kinetics of inflammatory and immunological components in rejection. Allograft gene expression measurments are also studied with the close collaboration of the pathology platform. Contacts: Pr. Jean-Paul Duong Van Huyen Dr. Marion Rabant |
TRANSCRIPTOMICS
This platform uses the nCounter Analysis System of NanoString™ to obtain a direct multiplexed measurement of gene expression with high levels of precision and sensitivity. This assay generates high-quality results from challenging sample types like FFPE tissues.
This platform also studies RNA Sequencing by NGS (Next Generation Sequencing) to further explore RNA expression profiles in kidney biopsies. Single-Cell RNA sequencing in tissue is also studied to improve our understanding of disease mechanisms in the allograt after kidney transplantation. It provides a higher resolution of cellular differences and a better understanding of the function of an individual cell in the context of its microenvironment. It is especially interesting in the context of renal transplantation as multiple cells from the tissue and the immune system interact at different levels. Contacts: Pr. Jean-Paul Duong Van Huyen Blaise Robin |
GENOM'ICThis platform is specialized in genomic and transcriptomic studies, integrating data production based on various technical approaches and adapted bio informatic analyses. Real time and digitale PCR, microarrays and Next-Generation Sequencing (NGS), Nanostring and 10X technologies are proposed, covering a large spectrum of analysis : for example, exploratory data obtained from RNA-seq will identify set of molecular markers linked with particular phenotypes of kidney transplantation ; focused analysis of this set with real time PCR or Nanostring technology will then be used to define a specific molecular signature for each phenotype.
Contact: Franck Letourneur |
Research |
Partnerships |
Paris Transplant Group |
SearchLEGAL NOTICE AND PRIVACY POLICY
© COPYRIGHT 2019. ALL RIGHTS RESERVED. LABS EXPLORER for the PARIS TRANSPLANT GROUP. |
